Clinical trials: Acute Cardiovascular Disease
AKI - Acute Kidney Injury, Cardiac Surgery
Urine Output Response to Fluid and Diuretic Therapy in Cardiac ICU Patients Monitored With FIZE kUO®
This prospective observational study evaluates the real-time urine output response to fluid therapy and diuretics in cardiothoracic intensive care unit (CTICU) patients monitored with the FIZE kUO® device.
- Conditions
- AKI - Acute Kidney Injury, Cardiac Surgery, Fluid Therapy, Hemodynamic Instability
- Trial name
- NCT07022314
- Testing
- FIZE kUO®
- Where
- Israel
- Volunteers
- 45 people
- Sponsor
- FIZE Medical ltd
Acute Ischemic Stroke
A Phase 1b Study to Assess the Safety and Tolerability of AB126 Neural Exosomes in Patients With Moderate to Severe Acute Ischemic Stroke
The goal of this clinical trial is to learn if AB126, an investigational treatment made from neural exosomes, is safe and well tolerated when given to adults with moderate to severe acute ischemic stroke (AIS) who have undergone…
- Trial name
- NEXIS (NCT07813130)
- Testing
- AB126 Neural Exosomes Intravenous Injection
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Aruna Bio, Inc.
Acute Myocardial Infarction, Acute Coronary Syndrome
Genetesis Accelerated Registry
Heart disease is the number one cause of death in the United States, with over 650,000 deaths in 2019 alone. Many healthy individuals possess key risk factors for heart disease which include but are not limited to high blood…
- Trial name
- GEAR (NCT05051228)
- Testing
- CardioFlux
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Genetesis Inc.
Acute Coronary Syndrome (ACS)
Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients
The primary objective is to describe the safety and tolerability of ticagrelor, by assessment of adverse events (characteristics, reporting rate, severity, relationship and risk factors), especially the bleeding events as defined…
- Trial name
- YingLong (NCT02430493)
- Where
- 15 sites in China
- Volunteers
- 1,066 people
- Sponsor
- AstraZeneca
Coronary Artery Disease
A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI
This study is designed to determine the efficacy of REG1 compared to bivalirudin in preventing periprocedural ischemic complications and major bleeding in patients undergoing PCI as a treatment for CAD.
- Trial name
- Regulate (NCT01848106)
- Testing
- pegnivacogin/anivamersen, Bivalirudin
- Where
- United States
- Volunteers
- 3,232 people
- Sponsor
- Regado Biosciences, Inc.
Myocardial Infarction, Myocardial Infarction, Acute
BIO monitorinG in Patients With Preserved Left ventricUlar Function AfteR Diagnosed Myocardial Infarction
The BIO|GUARD-MI study investigates whether continuous arrhythmia monitoring and the consequent treatment after detected arrhythmias in patients after myocardial infarction with preserved cardiac function, but other risk factors…
- Conditions
- Myocardial Infarction, Myocardial Infarction, Acute, Myocardial Infarction Old
- Trial name
- BIO-GUARD-MI (NCT02341534)
- Testing
- BioMonitor
- Where
- 59 sites in United States, Australia and 12 more
- Volunteers
- 802 people
- Sponsor
- Biotronik SE & Co. KG
Acute Ischemic Stroke
Cerebrolysin REGistry Study in Stroke - a High-quality Observational Study of Comparative Effectiveness
This study investigates the clinical practices, safety and effectiveness of Cerebrolysin in routine treatment of patients with moderate to severe neurological deficits after acute ischemic stroke.
- Trial name
- C-REGS2 (NCT03480698)
- Testing
- Cerebrolysin
- Where
- 8 sites in Austria
- Volunteers
- 1,851 people
- Sponsor
- Ever Neuro Pharma GmbH
Venous Thrombosis, Deep Vein Thrombosis
Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)
The purpose of this study is to compare the safety and efficacy of BAY59-7939 with the safety and efficacy of the licensed drug enoxaparin and a licensed oral vitamin K-antagonist and to find the optimal dose of BAY59-7939 for…
- Trial name
- NCT00839163
- Testing
- Xarelto (Rivaroxaban, BAY59-7939), Enoxaparin/Vitamin K-Antagonist
- Where
- 110 sites in Australia, Austria and 17 more
- Volunteers
- 613 people
- Sponsor
- Bayer
Aortic Aneurysm, Aortic Aneurysm and Dissection
A Study to Evaluate the Safety and Effectiveness of the Rapidlink Device When Used in Patients Undergoing an Open Surgical Procedure to Repair the Aorta
The Goal of this Clinical Study is to evaluate the safety and effectiveness of the Rapidlink device in the repair or replacement of the supra-aortic vessels during open surgical repair of aortic disease affecting the thoracic…
- Conditions
- Aortic Aneurysm, Aortic Aneurysm and Dissection, Aortic Diseases, Aneurysm of Aorta, Thoracic
- Trial name
- RAPID (NCT07078383)
- Testing
- Rapidlink
- Where
- 21 sites in United States, Austria and 3 more
- Volunteers
- 150 people
- Sponsor
- Vascutek Ltd.
Cerebrovascular Accident
Stroke in Young Fabry Patients (sifap1): Frequency of Fabry Disease in Young Stroke Patients
More than one million people in Europe suffer from a stroke every day. Normally older people have a stroke, but also a significant number of younger people between 18 and 55 years.
- Trial name
- sifap1 (NCT00414583)
- Testing
- No intervention
- Where
- 45 sites in Austria, Belgium and 12 more
- Volunteers
- 5,000 people
- Sponsor
- CENTOGENE GmbH Rostock
Hereditary Angioedema
C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)
Hereditary angioedema (HAE) is a rare disorder characterized by congenital lack of functional C1 esterase inhibitor. If not treated adequately, the acute attacks of HAE can be life-threatening and may even result in fatalities…
- Trial name
- NCT00292981
- Testing
- C1 Esterase Inhibitor
- Where
- 14 sites in United States, Canada
- Volunteers
- 57 people
- Sponsor
- CSL Behring
Myocardial Ischemia
Early Detection of Myocardial Ischaemia in Suspected Acute Coronary Syndromes by Apo J-Glyc
The objective of the study is to assess the performance characteristics of Apo J-Glyc as a novel biomarker for the early detection of myocardial ischaemia in patients with suspected acute coronary syndromes.
- Trial name
- EDICA (NCT04119882)
- Testing
- Blood collection
- Where
- 10 sites in Spain, United Kingdom
- Volunteers
- 404 people
- Sponsor
- Glycardial Diagnostics S.L.
Acute Coronary Syndrome
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile.
- Trial name
- dal-GenE-2 (NCT05918861)
- Testing
- Dalcetrapib
- Where
- 231 sites in United States, Canada and 1 more
- Volunteers
- 2,000 people
- Sponsor
- DalCor Pharmaceuticals
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia, Cancer
- Trial name
- NCT05153330
- Testing
- BMF-219
- Where
- 41 sites in United States, Greece and 3 more
- Volunteers
- 55 people
- Sponsor
- Biomea Fusion Inc.
Acute Coronary Syndrome
99th Percentile Upper Reference Limit (URL) for the Meritas Troponin I Test
Prospective multicenter sample collection and testing study.
- Trial name
- NCT02638311
- Where
- 3 sites in United States
- Volunteers
- 769 people, healthy volunteers welcome
- Sponsor
- Trinity Biotech
Acute Coronary Syndrome
A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome
Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots.
- Trial name
- PLATO (NCT00391872)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 672 sites in United States, Argentina and 42 more
- Volunteers
- 18,624 people
- Sponsor
- AstraZeneca
Aortic Dissection
A Real-World Study on Distal Aortic Remodeling for Stanford Type B Aortic Dissection With Fabulous Thoracic Aortic Stent System
To evaluate aortic remodeling of Fabulous thoracic aortic stent system in the treatment of acute and subacute Stanford type B aortic dissection (the changes of aortic diameter, cross-sectional area,and volume of true lumen, false…
- Trial name
- NCT05883592
- Testing
- Fabulous Thoracic Aortic Stent System
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Hangzhou Endonom Medtech Co., Ltd.
Coronary Artery Disease, Atherosclerosis, Coronary
Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
The objective of this study is to assess the safety and efficacy of the Orsiro Sirolimus Eluting Coronary Stent System in the treatment of subjects with up to three native de novo or restenotic (standard PTCA only) coronary…
- Conditions
- Coronary Artery Disease, Atherosclerosis, Coronary, Myocardial Ischemia, Ischemic Heart Disease
- Trial name
- BIOFLOW-V (NCT02389946)
- Testing
- Orsiro DES, Xience DES
- Where
- 92 sites in United States, Australia and 11 more
- Volunteers
- 1,334 people
- Sponsor
- Biotronik, Inc.
Stroke, Acute
Volumetric Impedance to Guide Stroke Response
Assess the ability of the Visor System to detect hemispheric bioimpedance asymmetry
- Trial name
- VIGOR (NCT03767842)
- Testing
- Visor System
- Where
- United States
- Volunteers
- 316 people
- Sponsor
- Cerebrotech Medical Systems, Inc.
Deep Vein Thrombosis, Venous Thrombosis
Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy
Following the findings of the clinical trials in drug development, this global non-interventional cohort field study will investigate rivaroxaban under clinical practice conditions in comparison with current standard of care for…
- Trial name
- XALIA (NCT01619007)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of care
- Where
- 21 sites in Austria, Belgium and 19 more
- Volunteers
- 5,145 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.